10.1172/jci45680 53 SheppardD
As a compounded preparation, it has not undergone FDA review for safety, effectiveness, or manufacturing quality as a finished product, and it should not be treated as equivalent to Ozempic or Wegovy - those are the FDA-approved, brand-name semaglutide products, manufactured and reviewed separately by Novo Nordisk
It analyzes pathway-level variants (FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction
Here's a checklist of essential documents and information you should compile before and during your legal process
References are listed in order of first citation in the text
In addition to agonists only target to GLP-1 receptors, agonists with multiple targets now are being developed